Protocol Ledger

NCT03517449 · Phase III · COMPLETED

Lenvatinib in Combination With Pembrolizumab Versus Treatment of Physician's Choice in Participants With Advanced Endometrial Cancer (MK-3475-775/E7080-G000-309 Per Merck Standard Convention [KEYNOTE-775])

Interventional Phase III clinical trial protocol NCT03517449 sponsored by Eisai in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2018-06-11 Enrollment: 827 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT03517449
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)827 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT03517449
Protocol FieldVerified Registry Value
NCT IdentifierNCT03517449
Consolidated Lead SponsorEisai
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase III
Overall Recruitment StatusCOMPLETED
Registered Enrollment827 participants (ACTUAL)
Registered Start Date2018-06-11
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Eisai across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI